MedPath

Varenicline for the Treatment of Cannabis and Tobacco Use Disorders in Veterans

Phase 2
Withdrawn
Conditions
Tobacco Use Disorder
Cannabis Use Disorder
Registration Number
NCT05294263
Lead Sponsor
VA Office of Research and Development
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Withdrawn
Sex
All
Target Recruitment
0
Inclusion Criteria

Inclusion Criteria:<br><br> - Meet DSM-5 criteria for cannabis use disorder and use cannabis at least 3 days per<br> week in the last 30 days.<br><br> - Meet DSM-5 criteria for tobacco use disorder and smoke at least five cigarettes or<br> report vaping 5 mg of nicotine daily.<br><br> - Males and female Veterans aged 18 and over.<br><br> - Be interested in quitting or reducing cannabis and tobacco use.<br><br> - If female and of childbearing potential, must agree to use acceptable methods of<br> birth control for the duration of the trial.<br><br> - Must consent to random assignment, and be willing to commit to medication ingestion.<br><br> - Must be able to read and provide informed consent.<br><br> - Must have body weight >110lbs (50kg) and have BMI between 18 and 35 kg/m2<br><br> - Must function at an intellectual level and have knowledge of the English language to<br> sufficiently allow for accurate completion of assessments.<br><br>Exclusion Criteria:<br><br> - Women who are pregnant, nursing, or plan to become pregnant during the course of the<br> study.<br><br> - Individuals with severe renal impairment.<br><br> - Lifetime history of DSM-5 Bipolar I or II Disorder, Schizophrenia or other psychotic<br> disorder. Stably treated MDD, Dysthymia, GAD, Social Phobia, PTSD, and Specific<br> Phobia diagnoses are acceptable (i.e. same dose of medication/psychotherapy has been<br> prescribed for at least 2 months prior to screening and no changes in current<br> medication/psychotherapy expected during course of the trial).<br><br> - Suicidal ideation or behavior within the past 6 months. Subjects who are believed to<br> be at suicidal (answers 'yes' on questions 4 or 5 of C-SSRS) or homicidal risk will<br> be referred to assessment by a mental health professional.<br><br> - Concomitant use of psychotropic medications, with the exception of stable doses<br> (defined as no dosing adjustments in the past two months) of non-MAO-I<br> antidepressants, non-benzodiazepine anxiolytics, and ADHD medications.<br><br> - Current use of medications prescribed for mania or psychosis (these medications may<br> be allowed if used for other indications)<br><br> - Current use of bupropion, amitriptyline or nortryptiline or other medication known<br> to have drug interactions with varenicline<br><br> - Moderate or severe non-cannabis substance use disorders within the past 60 days with<br> the exception of tobacco use disorder.<br><br> - Individuals taking an investigational agent within the last 30 days before baseline<br> visit.<br><br> - Individuals with clinically significant medical disorders or lab abnormalities.<br><br> - Individuals with clinically significant cardiovascular disease in the past 6 months<br> (e.g., myocardial infarction, CABG, PTCA, or severe or unstable angina).<br><br> - Individuals with clinically significant cerebrovascular disease in the past 6 months<br> such as TIA, CVA, or stroke<br><br> - Hypersensitivity to varenicline.

Exclusion Criteria

Not provided

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Number of cannabis using day as reported on Timeline Followback;Average number cigarettes smoked per day as reported on Timeline Followback
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath